Antidiabetic activity of eupafolin through peroxisome proliferator‐activated receptor‐gamma and PI3K/Akt signaling in Type 2 diabetic rats

• DOI: 10.1002/jbt.23463
• Publication Date: 2023-08-11T16:24:56Z
• Authors: Su Wu; Wenwei Ai; Lei Nie; Xiao Lu
• Keywords: GLUT4; IRS1

Abstract Eupafolin is a phyto compound of flavone that exerts anti‐inflammatory, antioxidant, and antiproliferative properties. The main purpose this study to examine the antidiabetic effect eupafolin on nicotinamide–streptozotocin (STZ)‐induced Type 2 diabetes (T2D) rats. After nicotinamide (120 mg/kg) treatment, STZ (60 was administrated intravenously induce T2D. Rats with fasting blood glucose (FBG) > 200 mg/dL are chosen for 7 days after T2D induction. treatment continued another 15 days. FBG an oral tolerance test (OGTT) were measured 21st day lipid, serum insulin, homeostatic model assessment (HOMA‐IR) determined. In liver homogenate, oxidative stress indicators measured. addition, expression proteins InsR, insulin receptor substrate (IRS)‐2, GLUT4, PPARγ, phosphatidylinositol 3‐kinase (PI3K)/Akt investigated using western blot. As by OGTT HOMA‐IR, reduced resistance (IR). Furthermore, when compared diabetic rats, antioxidant enzymes dramatically normalized. level glycogen in rats increased treatment. IRS‐2, PPARγ. Further, activated PI3K/Akt signaling These findings imply mechanism may be related activation PPARγ pathway result, flavonoid could medication comprehensive clinical investigation.